🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Recurrence Rate After Endoscopic Resection of , Laterally Spreading Tumor Granular Type (LST-G) of the Colon and Rectum: Endoscopic Mucosal Resection vs. Endoscopic Submucosal Dissection

RecruitingNAAges 18 Years - anyAllAzienda USL Reggio Emilia - IRCCS
NCT06815406 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Colorectal cancer is one of the leading causes of cancer-related mortality worldwide. Early-stage non-polypoid neoplastic lesions, particularly Laterally Spreading Tumors - Granular Type (LST-G) larger than 20mm, require effective endoscopic removal to prevent malignant progression. The two primary techniques for resecting these lesions are Endoscopic Mucosal Resection (EMR) and Endoscopic Submucosal Dissection (ESD). EMR is a widely used, minimally invasive technique that involves resecting the lesion with a diathermic snare after submucosal injection. While effective and safe, EMR often necessitates piecemeal resection, increasing the risk of local recurrence. In contrast, ESD, developed in Asia, allows for en bloc resection regardless of lesion size, ensuring more accurate histopathological assessment and lower recurrence rates. However, ESD requires greater technical expertise, has

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age ≥ 18 years. * Diagnosis of Laterally Spreading Tumor - Granular Type (LST-G) ≥ 20 mm in the colon or rectum with an indication for endoscopic resection. * Life expectancy \> 10 years. * Ability to understand and sign the informed consent form, demonstrating comprehension of the study and willingness to participate. Exclusion Criteria: * Diagnosis of Laterally Spreading Tumor - Non-Granular Type (LST-NG). * Presence of depressed areas within the lesion. * Lesions located on a scar or anastomosis site. * Lesions classified as Kudo Vi or Vn pattern. * History of chronic inflammatory bowel disease (e.g., ulcerative colitis, Crohn's disease). * Diagnosis of hereditary polyposis syndromes (e.g., familial adenomatous polyposis, Lynch syndrome).
💊

What it tests

  • Endoscopic Mucosal Resection (EMR)
  • Endoscopic Submucosal Dissection (ESD)
📍

Where

5 sites
IRCCS Azienda Ospedaliero Universitaria di Bologna - Sant'Orsola Malpighi
Bologna, Italy
Ente Ospedaliero Ospedali Galliera
Genova, Italy
Università Vita Salute - IRCCS
Milan, Italy
Ospedale Civile di Baggiovara
Modena, Italy
Azienda USL IRCCS di Reggio Emilia
Reggio Emilia, Italy
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy